Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Biogen Idec Inc. (BIIB), Sanofi SA (ADR) (SNY), Elan Corporation, plc (ADR) (ELN): The Greatest Thing Since Sliced Bread Has Arrived for MS Patients

Page 1 of 2

Last November, I examined five experimental drugs that appeared as if they had all of the tools necessary to become life-changing blockbusters from a financial and quality of life perspective. Yesterday, the first experimental drug I highlighted from Biogen Idec Inc. (NASDAQ:BIIB) was approved by the Food and Drug Administration as a first-line treatment for relapsing MS.

Biogen Idec Inc. (NASDAQ:BIIB)Pardon the cliche, but I believe the greatest thing since sliced bread has just been bestowed upon MS patients whether they realize it yet or not.

Greater efficacy with fewer side effects is possible!
Tecfidera — previously known as BG-12 in trials — was studied in two different clinical trials known as Confirm and Define. In its Confirm study, Biogen Idec Inc. (NASDAQ:BIIB) noted that its pill, administered twice daily, reduced the rate of MS relapses by an impressive 49%, and was associated with a 71% to 99% drop in new or expanding lesions in both trials.

What’s truly unique about Tecfidera is its adverse events profile, which demonstrates the promise of fewer side effects with better efficacy. The most common side effects exhibited by patients on Tecfidera were flushing and gastrointestinal events, which often resulted in very low trial dropout rates. Biogen’s new medication could also lower lymphocyte counts in patients, according to its press release.

However, compare this to Novartis AG (ADR) (NYSE:NVS)‘ Gilenya or Sanofi SA (ADR) (NYSE:SNY)‘s Aubagio and you’ll get a much clearer picture why Biogen Idec Inc. (NASDAQ:BIIB)’s oral medication appears superior.

Gilenya, which is approved as both a first-line and second-line MS treatment within the U.S. and comes in pill form as well, has the potential to cause serious cardiovascular problems through slowing a patients’ heart rate, can lower lymphocyte counts (similar to Tecfidera), and can potentially lead to macular edema or liver problems. Sure, it’s a once-daily pill compared to Tecfidera, which is required to be taken twice a day, but the side effects are night-and-day visible to me.

Aubagio, another pill-based drug from Sanofi SA (ADR) (NYSE:SNY), comes with even harsher warnings in the form of an FDA black box warning label. The warning specifically notes that Aubagio can cause severe liver problems that can lead to death. Additional side effects for the second-line treatment include kidney problems, high blood pressure, and breathing problems.

Page 1 of 2
Loading Comments...